Open Orphan plc changed its name to hVIVO plc on 26 October 2022, learn more
here
.
About Us
About hVIVO
Leadership Team
Our Companies
Key Stats
History
Services
Challenge Trials
RSV
Influenza
COVID-19
HRV
Malaria
Asthma & COPD
Laboratory Services
Assay Development
Field Trial Bio-logistics
Cell Based Assays
Molecular Services
Compound Efficacy & VRM
Biomarker Analysis
Phase II-III Clinical Trials
Vaccine Phase II-III Trials
Articles & Research
News & Media
Regulatory News
Media Coverage
Media Press Kit
Video Library
Events
Investors
New
Investors
Regulatory News & Email Alerts
Results Centre
Share Price Information
Events & Presentations
Environmental, Social & Governance
AIM Rule 26
Advisors
Documents
Corporate Governance
Volunteers
Careers
Contact Us
Contact Us
03 Oct 2022
Go Back
RSV Vaccines/Prophylactics: Key learning from the RSV challenge model and efficacy of vaccines
Share this:
Other recent posts
Blog
Advantages to Centralising Laboratory Services at hVIVO
Clinical field studies are a critical part of the drug development and approval process. They are conducted to evaluate the safety, immunogenicity, and efficacy of a new drug. These studies...
Read more
Blog
EMA’s updated guideline to include broader coverage on Human Challenge Trials
View Link
If you’re a potential customer, job seeker, health professional or an investor, find out how hVIVO can help you.
Contact hVIVO
twitter
facebook
envelope
linkedin
angle-down
xing
paper-plane
pinterest-p
whatsapp
commenting
meetup
chevron-down